Clinical Trial Update: A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy [Phase 2]

View source ↗

Summary

A Phase II open-label, single-arm study evaluating cadonilimab (AK104) in combination with chemotherapy for advanced non-small cell lung cancer with negative dr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cadonilimab (AK104) (Cadonilimab)

Snippet

Sponsor: Xin-Hua Xu | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING